Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone Capsule in Advanced Solid Tumors
NCT05700084Phase 2Active, not recruiting
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Oct 2025
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of utidelone in solid tumor and breast cancer (4 arms), sponsored by Beijing Biostar Pharmaceuticals Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 8 months, Dose-Limiting Toxicity at 8 months and 1 more. Started Jun 2023; status: active, not recruiting.
02
Drugs
utidelone
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT05700084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05700084.